(Q33390350)

English

Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maya Koren-Michowitz

1

object named as

Maya Koren-Michowitz

0 references

author name string

Philipp le Coutre

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Justus Duyster

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christof Scheid

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Panayiotis Panayiotidis

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Witold Prejzner

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jacob M Rowe

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michaela Schwarz

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Neta Goldschmidt

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Arnon Nagler

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4564-4572

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25351

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25351

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33390350&oldid=1584551513"